Ieq Capital LLC Invests $13.91 Million in Ventas, Inc. $VTR

Key Points

• Ieq Capital LLC purchased 156,680 Ventas shares in the second quarter, valued at approximately $13.91 million. Institutional investors collectively own 94.18% of the healthcare REIT.
• Analysts remain broadly positive, with 15 Buy ratings and three Holds; Ventas has a consensus rating of “Moderate Buy” and an average price target of $98.
• Ventas beat quarterly earnings expectations, reporting $0.97 per share versus $0.96 expected, while revenue rose 21.7% year over year to $1.73 billion.

Ieq Capital LLC purchased a new stake in shares of Ventas, Inc. (NYSE:VTR - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 156,680 shares of the real estate investment trust's stock, valued at approximately $13,913,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. raised its position in Ventas by 3.2% in the 4th quarter. Vanguard Group Inc. now owns 75,948,003 shares of the real estate investment trust's stock worth $5,876,856,000 after purchasing an additional 2,349,176 shares during the last quarter. BlackRock Inc. bought a new position in Ventas in the 2nd quarter valued at $4,953,439,000. State Street Corp boosted its position in Ventas by 2.5% in the 4th quarter. State Street Corp now owns 29,662,635 shares of the real estate investment trust's stock valued at $2,309,234,000 after buying an additional 735,620 shares during the last quarter. Geode Capital Management LLC boosted its position in Ventas by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 12,988,943 shares of the real estate investment trust's stock valued at $1,001,447,000 after buying an additional 475,633 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Ventas by 27.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,176,254 shares of the real estate investment trust's stock valued at $710,060,000 after buying an additional 2,000,341 shares during the period. Institutional investors and hedge funds own 94.18% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on VTR. Cantor Fitzgerald boosted their target price on Ventas from $97.00 to $102.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. KeyCorp raised their price target on Ventas from $90.00 to $95.00 and gave the company an "overweight" rating in a report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $100.00 price objective on shares of Ventas in a research report on Tuesday, June 16th. Raymond James Financial initiated coverage on Ventas in a report on Tuesday, June 16th. They set an "outperform" rating and a $94.00 price objective for the company. Finally, Wells Fargo & Company upped their target price on shares of Ventas from $93.00 to $96.00 and gave the company an "overweight" rating in a research report on Monday, June 1st. Fifteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, Ventas currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.00.

Ventas Stock Up 0.7%

Shares of Ventas stock opened at $93.32 on Friday. The business has a fifty day simple moving average of $91.36 and a 200 day simple moving average of $87.08. The stock has a market cap of $47.87 billion, a PE ratio of 172.81, a price-to-earnings-growth ratio of 2.15 and a beta of 0.69. The company has a quick ratio of 0.44, a current ratio of 0.44 and a debt-to-equity ratio of 0.86. Ventas, Inc. has a 12 month low of $66.38 and a 12 month high of $101.60.

Ventas (NYSE:VTR - Get Free Report) last released its earnings results on Wednesday, July 29th. The real estate investment trust reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.01. Ventas had a return on equity of 1.99% and a net margin of 4.08%.The firm had revenue of $1.73 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same quarter in the prior year, the firm posted $0.87 earnings per share. The company's quarterly revenue was up 21.7% on a year-over-year basis. Research analysts predict that Ventas, Inc. will post 3.89 EPS for the current year.

Insider Activity at Ventas

In related news, Director Michael J. Embler purchased 2,500 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $78.81 per share, with a total value of $197,025.00. Following the purchase, the director directly owned 19,202 shares in the company, valued at $1,513,309.62. The trade was a 14.97% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.53% of the stock is currently owned by company insiders.

Ventas Company Profile

Ventas, Inc NYSE: VTR is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas' business model combines property ownership with active asset management and capital markets activity.

Want to see what other hedge funds are holding VTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventas, Inc. (NYSE:VTR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source